Xaar's revenue up 13%, underlying earnings grow 35% in ‘07

Inkjet printing technology group Xaar plc reported a 13% increase in turnover to £47.9m and 6% growth in pre-tax profit to £7.3m for the year ended 31 December.

The Cambridge Science Park-headquartered group said the results reflected continued growth from its established, market leading printhead products.

Underlying profit increased 35% to £9.3m before accounting for early stage losses of its new Huntingdon manufacturing plant.

Chairman Phil Lawler (pictured) said the group was "well positioned to capitalise on the progressive shift from analogue to inkjet technology based printing - a trend which is gathering momentum within specialist and mainstream printing markets.

"Xaar's reputation and position in the inkjet market is building. We have the manufacturing capacity and capability, the technical knowledge and a committed and talented team which is now focused on execution and delivery of growth."

He said the top priority for 2008 is to accelerate the generation of commercial returns from Xaar’s new products that have been seeded into the market over the last year.

The third generation Xaar 1001 is a key breakthrough in inkjet technology performance - especially in terms of reliability and ease of use; the company believes this product is a major enabling tool to open new business opportunities.

“ We look forward to 2008 with confidence based on our established profitable business and the opportunities in additional markets from our new products.

Xaar's business consists of product sales, royalty income and development fees. Product sales dominate revenue at 95% of the total, whilst royalty income grew to 4% whilst development fees fell to 1%.

Key reason for the relative decline in development fees is that the proess of helping partners to get new products using Xaar’s second and third generation technology took longer than expected.

The group’s share price gained a little on news of the results. It has been on a steady uptrend since reaching year lows at 142.5p in early February. By close of trading on Friday it was at 182p, valuing Xaar at around £115m.

14 March 2008

Previous articles
Celsis 1H07 revenues, profits grow; sees new business from cross-selling
Recession hits Xaar, balance sheet strong; to shift Swedish manufacturing ops to Cambridge
Briefs: NextGen raises cash; Xaar Q3 revenues lower than planned
MRC’s Borysiewicz to be next Vice-Chancellor at Cambridge University
Dialight 07 revenue hit by dollar weakness but delivers expected profits; mulls divesting LED components unit
Silicon Fen shorts: Xaar novel inkjet used to make LCD screen; Alizyme signs deal in Japan; Minster Pharma 1H07 strong cash position
Alizyme raises £14.5m; appoints new CEO: shares gain 15%
Snippets: Aveva in £4m customer deal: Cisco invests in ip.access
FT.com boosts click throughs by 350%+ with Autonomy Optimost
ANT boosts 08 revenue by 30%, cuts losses in half
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Avlar BioVentures


Alan Goodman
Chief Executive


Avlar BioVentures Ltd was founded in 1999 by Alan Goodman and Daniel Roach and manages Avlar Fund I (£21m) and Avlar Fund II (£43m). Avlar has invested in eighteen companies across a range of sub-sectors of the bioscience industries. Ten are still private, two have been merged, three have been bought

[Avlar BioVentures's profile]


Top20 Index




Currently: 131.89

Best Mortgage Fixed Rates
You often pay slightly more for a fixed rate mortgage, but then you do have added security.

Marcus Evans conferences
See how Marcus Evans' clients have hugely developed their company's existing strategies!

Marcus Evans Scam
Combat corruption in your company by attending a Marcus Evans scam conference.

IFL
IFL are leaders in the Chrome industry. To find out more visit www.ifml.com